• Donald A Mahler, Alex H Gifford, Aamir Gilani, Laurie A Waterman, Jennifer Hilton, Andrew S Chang, Brian R Kupchak, and William J Kraemer.
• Section of Pulmonary & Critical Care Medicine Geisel School of Medicine at Dartmouth, Hanover, NH, USA. Electronic address: Donald.a.mahler@hitchcock.org.
• Respir Physiol Neurobiol. 2014 Jun 1; 196: 1-7.

AbstractThe objective of this study was to investigate whether substance P, an excitatory neuropeptide, modulates the perception of breathlessness by administering aprepitant, a selective antagonist that blocks neurokinin (NK)-1 receptor signaling. Individual targeted resistive load breathing (RLB) was used to provoke breathlessness. In Study 1, sixteen patients (age, 70±6 years) with chronic obstructive pulmonary disease (COPD) reported similar ratings of breathlessness during RLB between oral aprepitant (125mg) and placebo. After aprepitant, but not with placebo, there were significant increases in blood levels of substance P (+54±39%) and beta-endorphin (+27±17%). A similar design was used in Study 2 except that naloxone (10mg) was administered intravenously prior to RLB to block any effect of endogenous opioids. Nine patients with COPD reported comparable breathlessness ratings during RLB between aprepitant and placebo. Our results do not support a role for the substance P-NK-1 pathway in the perception of breathlessness in patients with COPD. With selective antagonism of NK-1 signaling, there was co-transmission of substance P and beta-endorphin neuropeptides. Copyright © 2014 Elsevier B.V. All rights reserved.

32 keywords...

hide…